Recently, two new subtypes have been proposed including, (1) antigen-presenting CAFs (apCAF) expressing major histocompatibility complex (MHC) class II genes associated with CD4+ T-cells deactivation, and (2) meflin, a membrane-anchored protein, -expressing CAFs (meflin-CAF), that reduces tumor progression [35]. Here, ISLR is linked to neoplasm.